Danaher Corporation 2008 10-K Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2008. Danaher Corporation is a multinational company operating in four segments: Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components. The company designs, manufactures, and markets professional, medical, industrial, commercial, and consumer products. In 2008, approximately 53% of sales were derived outside the United States.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Sales | $12.70 billion | $11.03 billion |
| Operating Profit | $1.87 billion | $1.74 billion |
| Net Earnings | $1.32 billion | $1.37 billion |
| Diluted EPS (Continuing Ops) | $3.95 | $3.72 |
| Operating Cash Flow | $1.86 billion | $1.70 billion |
| Total Debt | $2.62 billion | $3.73 billion |
| Cash and Equivalents | $393 million | $239 million |
| Operating Margin | 14.7% | 15.8% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 15.0% year-over-year. This was driven by acquisitions (10.5% growth), currency translation (2.0% growth), and organic growth from existing businesses (2.5%).
- Profitability: While operating profit increased, the operating margin declined from 15.8% to 14.7%. This compression was due to restructuring charges (65 basis points), the dilutive impact of acquisitions (80 basis points), and Tektronix-related charges.
- Restructuring: In Q4 2008, the company initiated restructuring actions resulting in $82.0 million in pre-tax charges ($61.5 million net of tax). This included workforce reductions of approximately 1,800 associates and 13 facility closures.
- Debt Reduction: Total debt decreased significantly from $3.73 billion to $2.62 billion, primarily due to the repayment of commercial paper used to finance 2007 acquisitions.
- Segment Performance:
- Professional Instrumentation: Sales surged 37.5% (driven by the Tektronix acquisition), though margins declined due to acquisition-related charges.
- Medical Technologies: Sales grew 9.5%, led by acute care diagnostics and life sciences.
- Industrial Technologies: Sales grew 3.5%, with weakness in product identification offsetting growth in motion and niche businesses.
- Tools & Components: Sales declined 3.0% due to weak North American demand in hand tools.
Guidance, Outlook, and Risks
- Economic Outlook: Management anticipates continued contraction in global demand in early 2009 due to the credit market turmoil and economic downturn. Industrial and consumer businesses are expected to be most impacted.
- Restructuring Costs: The company estimates an additional $40 to $60 million in pre-tax restructuring costs to be incurred in 2009.
- Capital Allocation: The company expects to continue managing working capital to maximize cash flow. It intends to seek to publicly issue debt securities in Q1 2009 to repay commercial paper.
- Risks: Key risks include deteriorating economic conditions, supply chain disruptions, foreign currency exchange rate fluctuations (strengthening USD negatively impacts reported sales), and the integration of acquired businesses.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and margin recovery of the Tektronix acquisition, which significantly impacted 2008 results and goodwill.
- Restructuring Execution: Monitor the realization of the projected $100 million in recurring pre-tax savings from Q4 2008 restructuring actions.
- Debt Maturity Profile: Review the company's ability to refinance its commercial paper and manage debt covenants given the tight credit markets.
- Foreign Currency Exposure: Assess the impact of a strengthening U.S. dollar on future reported sales and margins, as 53% of revenue is generated outside the U.S.
- Goodwill Impairment: Evaluate the sensitivity of the $9.2 billion goodwill balance to further economic downturns or market capitalization declines.